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On March 14, 2013, the 8th World Kidney Day (WKD) was
celebrated. WKD is an annual event jointly organized by the
International Society of Nephrology and the International
Federation of Kidney Foundations. This year, we aimed to
alert the public to the global increase in acute kidney injury
(AKI) in both developing and developed countries. AKI is a
syndrome of abrupt loss of kidney function, often with
oliguria, which is strongly associated with increased early
and long-term patient morbidity and mortality, as well as
the subsequent development of chronic kidney disease
(CKD).
There is an urgent need for a global health strategy to
reduce the enormous growing burden of AKI and its conse-
quences. We advocate that efforts focused on preventing
AKI be coupled with early detection and treatment, and
adequate follow-up to reduce mortality and the long-term
burden of AKI-induced CKD.
Epidemiology of AKI worldwide
The Kidney Disease Improving Global Outcome (KDIGO)
Clinical Practice Guideline for AKI defines AKI as any of the
following: increase in serum creatinine by 3.0 mg/L
(26.5 mM) within 48 hours; increase in serum creatinine to
1.5 baseline, which is known or presumed to have
occurred within the prior 7 days; or urine volume <0.5 mL/
kg/h for 6 hours.1 An epidemiological study in Scotland
showed that the incidence of AKI was 2147/million popu-
lation/year (pmp)2 and in a community study in northern
California, the annual incidence of nonedialysis-requiring
and dialysis-requiring AKI were respectively 3841 and 244
pmp3; this incidence increased over time and was consis-
tently higher in men and in the elderly.3 Unfortunately,
there are still no comprehensive studies on the incidence of
AKI in the community in the developing countries.* For the World Kidney Day Steering Committee 2013a
a World Kidney Day (WKD) is a joint initiative of the International
Society of Nephrology and the International Federations of Kidney
Foundations.
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AKI in 3.2e9.6% of admissions, with overall in-hospital
mortality around 20%, and up to 50% in intensive care unit
(ICU) patients.4,5 There is also increased long-termmortality
in those with AKI surviving hospitalization, with adjusted
mortality risk of 1.4, which augmented with increasing
severity of AKI.5 AKI requiring renal replacement therapy
occurs in 5e6% of ICU patients, with an extremely high in-
hospital mortality rate of 60%.6 It is estimated that about 2
million people die of AKI every year.6,7 Thosewho survive AKI
have a higher risk for later development of CKD.8
AKI in the developing countries
Eighty-six percent of the world’s population lives in low and
middle income countries, which have many contrasts and
inequalities. Sophisticated tertiary hospitals coexist with
inadequate primary care and poor health system infra-
structure in the same country and even in the same city. In
such countries, AKI has a peculiar bimodal presentation. In
modern, large, urban centers, the pattern of AKI is very
similar to that found in the developed countries; it is pre-
dominantly a hospital-acquired disease occurring mostly in
older, critically ill, multiorgan failure patients with sub-
stantial comorbidity. The main cause for AKI in this popu-
lation is renal ischemia, principally due to sepsis, and often
associated with nephrotoxic drugs.9
At the same time, in rural areas or smaller cities in the
countryside, AKI will usually be a community-acquired dis-
ease, affecting younger and previously healthy individuals.
In this population, specific causes of AKI include diarrheal
diseases with dehydration, infectious diseases (malaria,
dengue, yellow fever, leptospirosis, tetanus, and human
immunodeficiency virus), animal venoms (snakes, bees,
Loxosceles spiders, Lonomia caterpillars), septic abortion,
dyes, and natural medicines.10e12 Most of these factors
triggering AKI are associated with poverty and affect
vulnerable populations because of poor sanitation and
water hygiene (diarrheal diseases), a lack of education and
access to an adequate urban infrastructure and difficulty to
have access to the healthcare system (septic abortions,
snakebite, natural medicines, tetanus) and breaking of an. Published by Elsevier Taiwan LLC. All rights reserved.
2 Editorialecological balance from uncontrolled and unplanned ur-
banization (leptospirosis, yellow fever, Africanized bees,
and Lonomia caterpillar accidents).10e13 In the developing
countries, the same ICU may have a typical bacterial sepsis-
induced AKI patient side-by-side with a patient suffering
from dengue or tetanus-induced AKI.
Increasingly, these causes of AKI may be exported from
developing to developed countries due to immigration,
business travel, tourism, and global warming.
AKI in the developed countries
The availability of standardized criteria for diagnosis and
staging of AKI has made clear that the prevalence of AKI in
the developed countries has increased in the past
decade.14,15 AKI is now encountered in 45% of patients
admitted to the ICU and 20% of hospitalized patients.16,17
This increased prevalence probably reflects an aging pop-
ulation burdened by multiple comorbidities, which is often
managed with multiple drugs.18,19 AKI is a multifactorial
entity. Etiological factors include prerenal injury contrib-
uting to reduced renal perfusion, however the precipitating
events are often iatrogenic, such as hypotension during
anesthesia and surgery, or profound diarrhea secondary to
Clostridium difficile infection resulting from aggressive
antibiotic therapy.20 Drug-induced kidney injury is recog-
nized as a major factor in about 20% of cases, whereas
hospital-acquired infections, sepsis, complex surgery and
diagnostic procedures requiring intravenous contrast
continue to be significant risk factors for development of
AKI.21e23 Patients in ICU are dying of AKI and not just simply
with AKI. Experimental and small observational studies
have shown that AKI negatively affects immunity and is
associated with higher rates of infection.24 AKI patients
frequently develop a vicious cycle of immune dysfunction,
sepsis, and multiorgan failure. Indeed, severe sepsis is
currently the major cause of AKI in the USA.25 The host
response to sepsis involves an inflammatory response,
which activates innate immunity. If this persists, the im-
mune response will lead to a release of a multitude of
proinflammatory products, which frequently cause organ
dysfunction, including kidney failure.26
A key issue in the developed countries is that patients are
increasingly cared for by multiple providers, often in
different health care systems, with infrequent or minimal
data sharing between providers and across health care sys-
tems. This lack of knowledge often results in overdosing of
nephrotoxic medications; for example, a dentist might pre-
scribe large doses of nonsteroidal anti-inflammatory drugs
for pain management after dental surgery without the
knowledge of a patient’s underlying CKD, thus contributing
to development of AKI superimposed on the CKD. Because
kidney disease is generally silent, unless it is severe enough
to reduce urine output or lead to complications, it can often
go unrecognized.27 A recent national audit of the care pro-
vided to patients who died with a diagnosis of AKI in UK
hospitals revealed several shortcomings. AKI was often
diagnosed late in the course, the initial severity was under-
estimated, and diagnostic and therapeutic interventions
were often incomplete or delayed.28 This audit illustrates
the urgent need for improving awareness of AKI and has
prompted the medical community in the UK to implementspecific measures to facilitate early recognition, timely
diagnosis, and appropriatemanagement and follow-up of AKI
patients.29
AKI in children
The epidemiology of pediatric AKI has shifted in the past
decades from intrinsic kidney diseases (such as hemolytic
uremic syndrome and glomerulonephritis) to ischemia,
nephrotoxins, and sepsis in critically ill children.17 Estimates
of the incidence of AKI in children vary depending on the
definition used and the population assessed, but it is clearly
increasing. A pediatric-modified risk, injury, failure, loss,
and end-stage kidney (RIFLE) criterion was developed and
validated in 2007. The major difference with the original
RIFLE definition is the use of changes in estimated creatinine
clearance calculated by Schwartz formula rather than serum
creatinine, in view of the large variation in body mass in
children.17 Development of AKI has been consistently
demonstrated as an independent risk factor for death in
children, from neonates to adolescents. Recently, the
concept of “renal angina” was proposed as a tool to the early
identification of kidney injury together with early adoption
of preventive measures in children at high risk for develop-
ment of AKI.30 One of the strongest indicators of “renal
angina” and risk of further development of AKI in children is
fluid overload.17,30 As in adults, AKI carries a significant risk
for late development of CKD in surviving children.17,31
Other consequences of AKI
Apart from the high mortality associated with AKI, there are
other major consequences. Patients with AKI utilize more
resources and have longer hospital stays in part due to ef-
fect of AKI on other organ function. For instance, AKI pa-
tients have more difficulty being weaned off ventilators.32
AKI patients are more prone to fluid overload with a
resultant increase in mortality and impaired renal recov-
ery.33 When patients leave hospital they generally require
prolonged recuperation often in skilled nursing facilities
and may not recover kidney function.34 In a study of over
4000 type 2 diabetic patients in the Veterans Affairs
healthcare system in the USA, approximately half of the
patients required one or more hospitalizations, and among
those requiring hospitalization 29% experienced at least
one episode of AKI.35 CKD is now recognized as a major
noncommunicable disease, and data in the same study of
type 2 diabetics showed that AKI was an important inde-
pendent risk factor for stage 4 CKD (hazard ratio 3.56), with
each AKI episode doubling that risk. There is other consis-
tent and increasing evidence that AKI contributes to CKD
development and may result in dialysis dependency.8,36
Collectively these data demonstrate the high personal and
community costs of an episode of AKI and stress the
pressing need to address this problem in an effective way.37
Is AKI preventable and treatable?
A central tenet of the WKD message since 2006 has been
that “kidney disease is common, harmful, and treatable”.
Like CKD, AKI is common, harmful, and treatable, and is
also largely preventable.
Editorial 3The heterogeneity of patients and the broad range of
situations where AKI is encountered make it challenging to
standardize an approach for evaluating and managing pa-
tients with this syndrome. The recent KDIGO guidelines for
management of AKI provide a useful reference to assist
clinicians for managing AKI, however the successful imple-
mentation of guidelines and their application to individual
patients can be slow and requires concerted efforts.1,38
Prevention of AKI starts in the community with prompt
assessment of those at risk, for example, in taking prompt
action following effective evaluation of the severity of fluid
depletion in acute diarrhea. Regular drug therapy can
compound that risk and the many older people taking
nonsteroidal anti-inflammatory drugs or renin-angiotensin
system blockers should be educated to discontinue them
temporarily in the face of acute intercurrent illness, a so-
called “medication holiday”.
In the developed countries, the growing adoption of
electronic medical records provides several opportunities
for managing patients through the continuum of outpatient
and in-hospital care. Several studies have now shown that
active surveillance for changes in creatinine can automate
alerts to guide drug dosing and reduce the incidence of
drug-induced kidney injury.39,40 An “AKI sniffer system”
embedded in the electronic medical record to warn physi-
cians of changing renal function has been shown to increase
the number and timeliness of early therapeutic in-
terventions.41 The emerging field of kidney specific bio-
markers of damage will additionally offer opportunities to
improve care.42 Several studies have now shown the ability
of various biomarkers alone or in combination to facilitate
earlier diagnosis and improve differential diagnosis of AKI.
However, biomarker guided interventions have not as yet
been shown to be of benefit,43 and currently serum creat-
inine and urinary volume remain the clinical pointers to AKITable 1 Strategies for preventing acute kidney injury (AKI).
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Adapt renal replacement therapy todiagnosis. Given advances in medical informatics,
biomarker development and interpretation, and therapeu-
tic interventions, it is now imperative that we leverage
these advances to educate physicians and care providers
about AKI and provide them with the tools to manage these
patients timely and effectively.
In the hospital setting, AKI preventive measures
continue to be adequate hemodynamic control, hydration,
hematocrit and oxygen profiling, and avoidance of neph-
rotoxic drugs; other preventive maneuvers should be
implemented for particular diseases or conditions causing
AKI. In the developing countries, awareness of the specific
infectious or venomous organisms in certain areas will allow
environmental protection, vaccines, pharmacologic pro-
phylaxis, and early administration of antivenom. Early and
adequate antivenom administration is a valuable preven-
tive maneuver for snakebite and caterpillar venom-induced
AKI, reducing its morbidity and lethality.10,13 Prompt diag-
nosis, timely hemodialysis, and adequate supportive ther-
apy are associated with improved outcome in tropical
infectious disease-associated AKI, such as leptospirosis and
malaria.10,44,45 As always, the early diagnosis of AKI is the
key to minimize further insults.
Prevention for AKI is clearly the key to avoid the heavy
burden of mortality and morbidity associated with this
syndrome (Table 1), and this will only come about through
increasing awareness of the true incidence and clinical
impact of AKI among governments, the public, general and
family physicians, and other health care professionals. Most
etiologies of AKI can be prevented by interventions at the
individual, community, regional, and in-hospital levels.
Effective measures must include community-wide efforts to
increase the awareness of the devastating effects of this
illness and provide guidance on preventive strategies and
for early recognition and management. Efforts should beospital and community on AKI incidence, outcome,
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4 Editorialfocused on minimizing AKI causes, increasing awareness of
the importance of serial measurements of serum creatinine
in high risk patients and observing urinary volume to ach-
ieve early diagnosis. Protocols need to be developed to
systematically manage prerenal conditions and specific
infections.
Renal replacement therapy for AKI
When AKI patients require renal replacement therapy
(RRT), the current KDIGO recommendations are to deliver
an effluent volume of 20e25 mL/kg/h for continuous RRT or
to deliver a Kt/V of 3.9/week when using intermittent or
extended RRT.1 This requires careful monitoring as there is
often a significant reduction in the dose delivered versus
that prescribed.46 Peritoneal dialysis (PD) should also be
considered for AKI, particularly in developing countries,
because it is a simple, effective, safe, and relatively
inexpensive form of RRT.47 The technical simplicity of PD
and the potential to reduce costs if consumables can be
made locally, present an opportunity to establish cost-
effective programs for managing AKI as has been shown in
a recently established PD program for managing AKI in one
of the poorest countries in Africa.48
In conclusion, the worldwide celebration of WKD 2013
provides an opportunity to share the message that AKI is
indeed common, harmful, preventable, and treatable, and
that protecting the kidneys from this lethal syndrome is an
important health strategy for the patient and the commu-
nity. The effective implementation of such strategies will
only come when both the general public and the renal
community work together to convince health authorities of
the pressing need to do this. Government and health au-
thorities must allocate resources to manage this problem
both in the developed and developing countries.
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